Morepen Laboratories Ltd. (MOREPENLA): Morepen Laboratories 52 Week High Streak: Second Straight Session

Morepen Laboratories 52 Week High Streak has now held for its second straight session, with the stock trading within 2% of its 52-week high across the streak and advancing 1.95% cumulatively over those two sessions. The latest peak stood at Rs 126.90 while the stock was last traded at Rs 123. The latest Univest figures confirm the near-high pattern, but they do not establish a company-specific catalyst for the repeated move.

Morepen Laboratories Ltd. (MOREPENLA) last traded at Rs 123 versus the previous close of Rs 120.90, after opening at Rs 121.35 and touching a low of Rs 120.90. Turnover stood at Rs 10.86 crore and market capitalisation at Rs 6,624.76 crore. For readers, the key signal is not just the day move but the fact that the stock has stayed near its yearly high again, which keeps it in the spotlight as a Morepen Laboratories Share Price story and a broader Morepen Laboratories Stock News theme.

Morepen Laboratories 52 Week High Streak: Consecutive High Analysis

Metric	Value
Current Price	Rs 123
Previous Close	Rs 120.9
Today's Move	+Rs 2.1 (+1.74%)
Open	Rs 121.35
High	Rs 126.9
Low	Rs 120.9
Turnover	Rs 10.86 crore
Market Capitalisation	Rs 6,624.76 crore

Morepen Laboratories Ltd. (MOREPENLA) traded at Rs 123 versus the previous close of Rs 120.9, a rise of 1.74%. The stock opened at Rs 121.35, reached a high of Rs 126.9 and touched a low of Rs 120.9.

The intraday setup showed a firm start and a wide range, with Morepen Laboratories trading above the previous close for much of the move and touching a high of Rs 126.90. The stock is last traded at Rs 123, up Rs 2.10 or 1.74% from the previous close of Rs 120.90. It opened at Rs 121.35 and touched a low of Rs 120.90, placing the current price near the upper half of the day’s range.

Turnover of Rs 10.86 crore indicates normal market activity for a stock of this size, while market capitalisation of Rs 6,624.76 crore keeps Morepen Laboratories within the healthcare universe that often sees strong investor attention around earnings, product launches and valuation resets. For search readers tracking Morepen Laboratories Share Price Today, this is a stock that remains close to its 52-week high rather than one that has simply moved on a single headline.

What the Repeated 52-Week Highs Show

Morepen Laboratories 52 Week High Streak is the main story here: the stock has traded within 2% of its 52-week high for its second straight session, and the cumulative move across the streak is 1.95%. That pattern matters because it shows the share price has stayed near the one-year peak across more than one trading day, rather than briefly touching the level and moving away.

What this repeated strength does not do is explain why the stock has remained near the high. The latest Univest figures confirm the price pattern, but they do not identify a company-specific trigger. So the correct reading is factual and restrained: Morepen Laboratories is part of the current list of Stocks Hitting 52 Week Highs and remains in the conversation around Morepen Laboratories Back To Back 52 Week Highs, yet the reason for the persistence is not established by the numbers alone.

That makes the Morepen Laboratories 52 Week High Streak useful as a market signal, not a narrative conclusion. A stock that can stay this close to its yearly high across multiple sessions is telling readers that the market is still valuing it near recent peaks, even if the exact driver is not visible from the data set used here.

Morepen Laboratories Ltd. (MOREPENLA) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 6,624.76 crore
P/E Ratio	47.14x
P/B Ratio	5.09x
ROE	7.96%
ROCE	10.19%
EPS	Rs 2.56
Book Value Per Share	Rs 23.78
Dividend Yield	0.17%

Morepen Laboratories Ltd. (MOREPENLA) fundamental metrics show P/E 47.14x, P/B 5.09x, ROE 7.96%, ROCE 10.19%. These figures provide context only and are not a buy or sell signal.

Morepen Laboratories Ltd. has a market capitalisation of Rs 6624.76 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 47.14x, P/B at 5.09x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 7.96% and ROCE of 10.19%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 2.56, book value per share of Rs 23.78, dividend yield of 0.17%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 28.19x, median ROE of 11.7%, median ROCE of 13.61%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	47.14x
Benchmark Median P/E	28.19x
Benchmark Average P/E	40.37x
Benchmark P/E Range	0x to 683.5x
Company P/B Ratio	5.09x
Benchmark Median P/B	3x
Company ROE	7.96%
Benchmark Median ROE	11.7%
Company ROCE	10.19%
Benchmark Median ROCE	13.61%
Company Market Capitalisation	Rs 6,624.76 crore
Benchmark Median Market Cap	Rs 677.56 crore

Morepen Laboratories Ltd. (MOREPENLA) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Morepen Laboratories Ltd. (MOREPENLA) has a P/E ratio of 47.14x, which is above the benchmark median of 28.19x, a difference of +67.22%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Morepen Laboratories Ltd. (MOREPENLA) has a ROE of 7.96%, which is below the benchmark median of 11.7%, a difference of -31.97%. Morepen Laboratories Ltd. (MOREPENLA) has a ROCE of 10.19%, which is below the benchmark median of 13.61%, a difference of -25.13%.

Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Innova Captab Ltd.	INNOVACAP	6,756.83	43.23	5.95	13.75	15.04
SENORES PHARMACEUTICALS L	SENORES	6,474.21	51.23	6.72	14.14	15.66
SYMBIOTEC PHARMALAB LTD	SYMBIOTEC	7,024.8	63.92	4.73	11.22	12.41
Sanofi India Ltd.	SANOFI	7,111.86	21.96	8.61	44.5	55.46
Bliss GVS Pharma Ltd.	BLISSGVS	7,234.73	53.12	5.87	12.11	17.4

Morepen Laboratories Ltd. (MOREPENLA) has a P/E ratio of 47.14x compared with the displayed peer median of 51.23x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 7.96% compares with a peer median of 13.75% across the companies shown in the table. ROCE stood at 10.19% versus the displayed peer median of 15.66%, providing a capital-efficiency comparison. Morepen Laboratories Ltd. (MOREPENLA) has a market capitalisation of Rs 6,624.76 crore. Among the 5 peers shown, 4 have a larger market capitalisation.

Why Investors Are Watching Morepen Laboratories

• The stock is holding near its 52-week high for a second straight session.
• Cumulative movement across the streak is 1.95%, keeping the share price near the yearly peak.
• Valuation remains above the industry median on both P/E and P/B.
• The company sits in the active Healthcare and Pharmaceuticals & Drugs space.
• Market capitalisation and peer comparisons place it in a closely watched price band.

About Morepen Laboratories

Morepen Laboratories Ltd. is listed on NSE and BSE and operates in the Pharmaceuticals & Drugs industry within the Healthcare sector. The company has a market capitalisation of Rs 6,624.76 crore, which keeps it in the mid-sized bracket of listed healthcare names by market value, without changing the underlying business profile.

From a stock market perspective, Morepen Laboratories is being tracked for its share price behaviour, its valuation versus peers, and how the company continues to trade near its 52-week high. That makes the current Morepen Laboratories Stock News flow relevant not just to short-term traders but also to readers comparing fundamental ratios and sector positioning.

Track Morepen Laboratories on Univest

Follow Morepen Laboratories Ltd. (MOREPENLA) on Univest for the latest share price update, company news, market update and sector comparison. The stock page brings together the key numbers readers need to monitor the Morepen Laboratories 52 Week High Streak and the broader Morepen Laboratories Stock Analysis in one place.

You can also use the stock page to revisit the company’s P/E ratio, P/B ratio, ROE, ROCE, EPS and book value as new market information comes in. That helps keep the Morepen Laboratories Share Price view aligned with changing market conditions and peer comparisons.

Frequently Asked Questions

What is the Morepen Laboratories 52 Week High Streak right now?

Ans. Morepen Laboratories 52 Week High Streak is at a second straight session. The stock has traded within 2% of its 52-week high across both sessions, making the current move more than a one-day appearance near the yearly peak.

How much has Morepen Laboratories moved across the streak?

Ans. According to the latest Univest figures, the cumulative move across the streak is 1.95%. That is the figure to track when judging the repeated near-high pattern rather than focusing only on the current intraday change.

Has Morepen Laboratories set a new 52-week high today?

Ans. No. The stock has traded near its 52-week high, but the data confirms proximity rather than a fresh record. The latest peak shown is Rs 126.90, while the last traded price is Rs 123.

What does the repeated near-high pattern indicate?

Ans. It indicates that the share price has stayed close to its one-year high for more than one session. The data confirms the pattern, but it does not establish a company-specific catalyst for the continued move.

Is Morepen Laboratories expensive compared with peers?

Ans. On the given numbers, Morepen Laboratories trades above the industry median on both P/E and P/B. That makes it richer than the typical company in the peer set, even though valuation alone does not describe business quality.

How does Morepen Laboratories compare on profitability?

Ans. ROE is 7.96% and ROCE is 10.19%, both below the industry medians of 11.70% and 13.61%. That makes the current valuation-versus-return mix important to watch alongside the share price trend.

What should investors monitor next in Morepen Laboratories stock news?

Ans. Investors should track whether the stock stays near its 52-week high, how valuation compares with the peer set, and whether fresh company updates alter the current share price pattern. Those are the main factual checkpoints at this stage.

Why is Morepen Laboratories appearing in stocks at one-year high today searches?

Ans. Because the stock is trading close to its 52-week peak for a second straight session. That places it within the group of Stocks At One Year High Today and keeps it visible in Stocks In News Today lists.

Track Morepen Laboratories Ltd. (MOREPENLA) Share Price on Univest

Use Morepen Laboratories Ltd. (MOREPENLA) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.